Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Details

Ressource 1Download: BIB_EB4FE1C2D1D7.P001.pdf (1339.10 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_EB4FE1C2D1D7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Journal
Journal For Immunotherapy of Cancer
Author(s)
Yuan J., Hegde P.S., Clynes R., Foukas P.G., Harari A., Kleen T.O., Kvistborg P., Maccalli C., Maecker H.T., Page D.B., Robins H., Song W., Stack E.C., Wang E., Whiteside T.L., Zhao Y., Zwierzina H., Butterfield L.H., Fox B.A.
ISSN
2051-1426 (Electronic)
ISSN-L
2051-1426
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
4
Pages
3
Language
english
Abstract
The culmination of over a century's work to understand the role of the immune system in tumor control has led to the recent advances in cancer immunotherapies that have resulted in durable clinical responses in patients with a variety of malignancies. Cancer immunotherapies are rapidly changing traditional treatment paradigms and expanding the therapeutic landscape for cancer patients. However, despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Thus, there is a growing need to identify predictive and prognostic biomarkers that enhance our understanding of the mechanisms underlying the complex interactions between the immune system and cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) reconvened an Immune Biomarkers Task Force to review state of the art technologies, identify current hurdlers, and make recommendations for the field. As a product of this task force, Working Group 2 (WG2), consisting of international experts from academia and industry, assembled to identify and discuss promising technologies for biomarker discovery and validation. Thus, this WG2 consensus paper will focus on the current status of emerging biomarkers for immune checkpoint blockade therapy and discuss novel technologies as well as high dimensional data analysis platforms that will be pivotal for future biomarker research. In addition, this paper will include a brief overview of the current challenges with recommendations for future biomarker discovery.
Pubmed
Open Access
Yes
Create date
19/06/2016 17:41
Last modification date
20/08/2019 17:13
Usage data